REGARD: A phase 3, randomized, double-blind trial of ramucirumab (RAM) and best supportive care (BSC) versus placebo (PL) and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression (PD) on first-line platinum- and/or fluoropyrimidine-containing combination therapy: Age subgroup analysis.

被引：4

作者：

Fuchs, Charles S.

Tomasek, Jiri

Cho, Jae Yong

Tomasello, Gianluca

Goswami, Chanchal

dos Santos, Lucas Vieira

Aprile, Giuseppe

Ferry, David

Melichar, Bohuslav

Tehfe, Mustapha Ali

Tehfe, All

Topuzov, Eldar

Zalcberg, John Raymond

Chau, Ian

Tabernero, Josep

Hsu, Yanzhi

Schwartz, Jonathan D.

Koshiji, Minori

Safran, Howard

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Masaryk Univ, Fac Med, Masaryk Mem Canc Inst, Brno, Czech Republic

[3] Gangnam Severance Hosp, Seoul, South Korea

[4] Ist Ospitalieri Cremona, Cremona, Italy

[5] BP Poddar Hosp, Kolkata, India

[6] Med Res Ltd, Kolkata, India

[7] Univ Campinas UNICAMP, Sao Paulo, Brazil

[8] Azienda Osped Univ, Udine, Italy

[9] New Cross Hosp, Wolverhampton, England

[10] Palacky Univ, Med Sch & Teaching Hosp, CR-77147 Olomouc, Czech Republic

[11] Hop Notre Dame CHUM, Montreal, PQ, Canada

[12] Peter MacCallum Canc Ctr, Melbourne, Australia

[13] Royal Marsden NHS Fdn Trust, London, England

[14] Royal Marsden NHS Fdn Trust, Surrey, England

[15] Vall dHebron Univ Hosp, Barcelona, Spain

[16] ImClone Syst, Bridgewater, NJ USA

[17] ImClone Syst, Branchburg, NJ USA

[18] ImClone Syst, Kobe, Hyogo, Japan

[19] Brown Univ, Oncol Res Grp, Providence, RI 02912 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.4057

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

4057

引用

页数：1